X

Stay Connected

Sign Up for Updates

 
We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.
Katie Koziara

Katie Koziara is a director of public affairs at PhRMA focusing on the organization’s executive visibility work and media relations strategy. She previously ran the social media strategy for a D.C.-based non-profit working on federal management and leadership issues. Katie earned her B.A. in Public Policy from the University of Michigan’s Ford School and is currently earning her M.A. in Fiction Writing from Johns Hopkins University.

Recent Posts

How HTA-based price controls could worsen health outcomes and health disparities

By Katie Koziara  |    November 22, 2022
Concerns about the cost of health care have led to calls for the use of health technology assessments or HTAs by the federal government. This would allow government agencies to make important...   Read More

Traditional HTA methods treat everyone like the “average” patient

By Katie Koziara  |    November 7, 2022
Concerns about the cost of health care have led to calls for the use of health technology assessments or HTAs by the federal government. This would allow government agencies to make important...   Read More

Busting 3 Myths About Copay Coupons

By Katie Koziara  |    October 5, 2022
Insurer-imposed barriers like high deductibles and coinsurance shift the cost of life-saving care onto patients. Manufacturers and others have stepped forward to assist patients who face high...   Read More

Making coupons count for patients at the pharmacy counter

By Katie Koziara  |    August 25, 2022
Too many patients face high out-of-pocket costs for brand medicines, even when they have insurance.   Read More

Potential gene therapies bring hope to patients with sickle cell disease

By Katie Koziara  |    June 6, 2022
A recent analysis highlights how potential gene therapies have the potential to dramatically reduce income disparities for patients with sickle cell disease, leading to as much as $21,000 more in...   Read More

Study finds important health outcomes are not included in cost-effectiveness analyses for sickle cell, Alzheimer’s and MS treatments

By Katie Koziara  |    May 19, 2022
A new study from the Office of Health Economics (OHE) confirmed that the EQ-5D, a tool commonly used in health technology assessments (HTAs) often excludes outcomes important to patients and their...   Read More

Gene therapies can reduce treatment burden and costs for patients with blood disorders

By Katie Koziara  |    May 18, 2022
A new analysis found potential gene therapies for blood disorders like hemophilia, beta thalassemia, and sickle cell disease hold promise in dramatically reducing existing treatment burdens for...   Read More

Annual projections from NHE compared to actual health care spending

By Katie Koziara  |    May 5, 2022
The Centers for Medicare & Medicaid Services (CMS) recently released their National Health Expenditure (NHE) projections of health care spending in the United States through 2030. While these data...   Read More

Innovative contracts continue to gain traction and improve quality of care

By Katie Koziara  |    May 2, 2022
Innovative contracts can help bring more value to patients and the health care system. These types of payment arrangements can include:   Read More

What’s really happening when it comes to prescription drug costs

By Katie Koziara  |    April 27, 2022
New data show how robust competition continues to keep national spending on life-saving medicines in check, even as new innovative treatments reach patients. According to the latest report by the...   Read More

Search the Catalyst

View Posts by Topic

see all

View Posts by Contributor

View Posts by Date

see all

Subscribe to Email Updates